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genotypes were HPV 16, 53, and 52 with a prevalence of
26.4, 16.4, and 13.6%, respectively.  Conclusion: The epide-
miological characterization of HPV infections described in 
this study might guide actions for epidemiological surveil-
lance to strengthen the program in Bogotá and to develop 
appropriate HPV vaccination programs. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Cervical cancer is an important public health issue 
worldwide  [1] , representing the fourth most common 
cancer in women and the seventh overall, with an esti-
mated 528,000 new cases in 2012  [2] . In this sense, Africa, 
Asia, and Central and South America account for 70% of 
the world cancer deaths  [3] .
 In Colombia, the annual rate of cervical cancer is 18.2 
cases per 100,000 women, making it one of the countries 
with the highest incidence of this type of cancer  [4] . This is 
the reason why the Program for the Detection and Control 
of Cervical Cancer (PDCCC), implemented in a network 
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 Abstract 
 Objectives: To estimate the frequency of human papilloma-
virus (HPV) infection and the genotype distribution of HPV 
among women with a Pap smear showing atypical squa-
mous cells of undetermined significance (ASC-US) attending 
the Program for the Detection and Control of Cervical Cancer 
in Bogotá, Colombia. Study Design: Cervical samples from 
200 women with an ASC-US Pap smear were analyzed for
the presence of HPV DNA and genotype distribution using a 
commercial molecular technique (Linear Array ® ; Roche Mo-
lecular Systems, USA).  Results: HPV infection was found in 
140 women (70%). High-risk HPV types were present in 
46.4% of the samples; 16.4% showed a low-risk HPV type, 
and 37.1% showed both. Of the positive samples, 42.9% 
were infected with a single viral genotype, whereas 57.1% 
exhibited multiple HPV infections. The most common HPV 
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of public hospitals in Bogotá, Colombia, uses cervical cy-
tology screening for the early detection of abnormalities 
which may eventually progress to cancer. Although in the 
last 40 years this strategy has dramatically decreased the 
disease incidence and mortality worldwide  [5] , several 
studies have shown that this approach does not contribute 
to the timely management of cervical disease  [6] since it 
does not detect the presence of human papillomavirus 
(HPV), a prerequisite for cervical carcinogenesis  [7] .
 HPV is a common sexually transmitted virus  [8] tight-
ly associated with the development of cervical cancer. Ge-
netic analysis of cervical carcinomas has revealed that 
nearly 99.7% of cervical squamous carcinomas contain 
DNA of this virus  [6] . However, this relationship has been 
established only with certain viral genotypes, mainly 
HPV 16 and HPV 18, considered high-risk (HR) HPV 
types because of their oncogenic potential to cause prolif-
eration of malignant cells in the cervical epithelium  [4] . 
These 2 genotypes are responsible for 60–80% of all cervi-
cal cancers  [9] . On the other hand, low-risk (LR) HPV 
types have been associated with the development of gen-
ital warts  [10] .
 Basically, virus particles can enter the epithelium 
through microabrasions generated during sex  [11] . The 
HPV cycle induces the proliferation of basal and para-
basal cells, leading to the disruption of epithelial differen-
tiation and generating changes in tissue structure and 
physiology, which contribute to the pathogenesis of cer-
vical cancer  [12] . Squamous abnormalities are identified 
through cervical cytology according to the Bethesda Sys-
tem (2014), and they comprise: atypical squamous cells 
(ASC), including ASC of undetermined significance 
(ASC-US), where ASC cannot exclude H-SIL; low-grade 
squamous intraepithelial lesions, including low-grade 
dysplasia; high-grade squamous intraepithelial lesions, 
including moderate and severe dysplasia (CIN II AND 
CIN III), and squamous cell carcinoma  [13] .
 The ASC-US category involves the largest number of 
abnormal cytology reports  [14] , without establishing as 
such benign or malignant cellular changes. In fact, it 
highlights the factors that can lead to transient changes in 
cervical epithelium  [15] . Consequently, there is no con-
sensus on the inclusion of women with an ASC-US diag-
nosis in the program, leading to a risk of disease progres-
sion in this particular group of women. Current patient 
management guidelines recommend the use of HR HPV 
DNA testing as a triage method to identify women  ≥ 21 
years old with ASC-US who are at an increased risk of 
cervical cancer and thus determine the need for referral 
for colposcopy exploration  [16] .
 The aim of the present study was to determine the 
type-specific prevalence of HPV using the commercial 
molecular technique Linear Array ® (Roche Molecular 
Systems, USA) in a set of 200 cervical cytology samples 
obtained from women with an ASC-US diagnosis belong-
ing to the PDCCC of Bogotá.
 Materials and Methods 
 The study population included 200 women with a cytological 
diagnosis of ASC-US enrolled into the PDCCC from a public hos-
pital network in Engativá, a public hospital affiliated with the 
health system of Bogotá. Participants consulted the program be-
tween March and October 2014 and agreed to voluntarily partici-
pate in this study by providing informed consent. Patients between 
17 and 63 years of age were included in this study. Information on 
sociodemographic characteristics, medical history, and sexual and 
reproductive behavior was obtained at the time of the gynecologi-
cal visit. Pregnant women or women diagnosed with other cervical 
diseases were excluded. The management protocol of the partici-
pants is shown in  figure 1 . This study was approved by the Ethics 
Committee of the Secretaría de Salud de Bogotá.
 Collection of Cervical Samples and Personal Information 
 Prior to colposcopy, cervical samples were taken from each
patient using a cytobrush and preserved in transport medium 
(COBAS ® PCR Cell Collection Media; Roche Molecular Systems) 
following the manufacturer’s instructions. The samples were 
stored at room temperature until processing at the Laboratory of 
Public Health, Bogotá.
 HPV Detection and Typing 
 Type-specific identification of HPV genotypes was performed us-
ing the Linear Array technique (Roche Molecular Systems) accord-
ing to the manufacturer’s instructions. This technique allows the 
identification of 37 HPV genotypes, including 14 HR genotypes (i.e. 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and 23 LR viral 
types (i.e. 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 
81, 82, 83, 84, IS39, and CP6108), which are widely used in epide-
miological studies. The Linear Array HPV test (Roche Molecular 
Systems) has 96% sensitivity and 99% specificity to detect DNA from 
HR HPV types (Linear Array HPV Genotyping Test ® ; Roche). Ex-
traction, amplification, and hybridization steps allow identification 
of both the target viral genetic material and a fragment of the human 
β-globin gene, used as the internal control in sample processing.
 Statistical Analysis 
 The sample size was calculated considering the number of cyto-
logical samples analyzed during the year 2012 and the expected 
prevalence of 4% due to an ASC-US diagnosis. Accordingly, it in-
cluded 160 samples (95% reliability and 3% error). However, since 
the number of samples collected during the sampling period was 
large, the sample size was increased to 200 specimens. The HPV 
frequency distribution was analyzed, with data collected in a data-
base developed in Microsoft Excel ® . A bar graph showing single 
and multiple infections was created using the same software. Con-
fidence intervals (CI) for the overall HPV prevalence and type-spe-
cific viral prevalences were calculated using Epi Info 3.5.1 software.
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 Results 
 A total of 200 women with an ASC-US diagnosis were 
included in this study (mean age 35.9 ± 11.42 years). The 
highest prevalence of ASC-US diagnosis was recorded 
among women aged 25–34 years ( table 1 ). Briefly, 20.5% 
(CI 15.26–26.89%) of women with ASC-US were below 
24 years of age, 27.5% (CI 21.55–34.33%) were aged 25–
34 years, 24.5% (CI 18.83–31.16%) were aged 35–44 years, 
22.5% (CI 17.03–29.04%) were aged 45–54 years, and 
4.5% (CI 2.21–8.64%) were over 55 years of age. Data 
were missing for 1 patient.
 The molecular analysis demonstrated that all of the 
200 samples were suitable for HPV detection and typing 
according to the results obtained via β-globin gene frag-
ment amplification. Viral DNA analysis showed that 140 
of the 200 women (70.0%, CI 63.45–76.55%) had HPV 
infection. Thirty-two different HPV genotypes were 
identified in the samples using this commercial molecular 
technique ( fig. 2 ). Eighteen LR HPV types (HPV 53, 70, 
84, 42, 61, 54, 62, 81, 6, CP6108, 71, 73, IS39, 55, 72, 83, 
67, and 69) and 14 HR genotypes (i.e. HPV 16, 52, 58, 59, 
39, 18, 31, 45, 66, 56, 35, 33, 51, and 68) were identified 
among the ASC-US lesions. The most common HR HPV 
type was HPV 16, with a prevalence of 26.4% (CI 19.50–
34.66%), and HPV 52, 58, 59, 39, 18, 31, 45, 66, 56, 35, and 
59 were the top 11 most commonly detected HPV geno-
types in women with ASC-US ( fig. 2 ). HPV 18 and 31 had 
the same low frequency (i.e. 7.9%, CI 4.18–13.95%). 
Moreover, the most commonly detected LR HPV geno-
types were HPV 53, 70, 84, 42, and 61, with a prevalence 
of 17.1% (CI 10.90–23.84%), 9.3% (CI 5.23–15.66%), 
6.4% (CI 3.16–12.20%), and 5.7% (CI 2.68–11.31%) for 
the last 2 LR types, respectively. Surprisingly, the preva-
lence of HPV 6 was lower than 5% and HPV 11 was not 
detected in the studied cervical samples.
 Nearly 60% (n = 81) of the patients positive for HPV 
infection were younger than 34 years and HPV positivity 
decreased with increasing age, with the highest preva-
lence appearing in women aged 25–34 years ( table  1 ). 
About 60% (n = 81) of the patients positive for HPV in-
fection were younger than 34 years and HPV positivity 
decreased with increasing age, with the highest preva-
lence appearing in women aged 24 years or younger ( ta-
ble 1 ).
 Molecular analysis showed that 42.9% (CI 35.79–
50.01%) of the HPV-positive samples had single infec-
tions, whereas 57.1% (CI 49.99–64.21%) had multiple in-
 Table 1.  HPV positivity distribution by age group in women with 
ASC-US 
Age group, 
years
Study population, 
n (%)
HPV positivity
n (%)  95% CI
<24 41 (20.5) 38 (92.68) 78.99 – 98.09
25 – 34 55 (27.5) 43 (78.18) 64.63 – 87.75
35 – 44 49 (24.5) 34 (69.39) 54.42 – 81.32
45 – 54 45 (22.5) 20 (44.44) 29.95 – 59.87
>55 9 (4.5) 5 (55.56) 22.65 – 84.65
Unknown 1 (0.5) 0 (0) 0
Women aged <24 years had the highest prevalence of viral in-
fection.
Smear test performance in
a public hospital network
Cytological diagnosis of ASC-US
(n = 200)
Colposcopy
(n = 200)
Type-specific identification of
HPV genotypes
Negative
(n = 151)
Positive
(n = 49)
Positive HR
HPV, LR HPV, or
HR-LR HPV
Negative
 Fig. 1. Study protocol of patients with an ASC-US diagnosis en-
rolled into the PDCCC (Bogotá, 2014). 
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fections. The HPV 16 genotype most frequently present-
ed as a single infection (10% of the samples), followed by 
HPV 52 and HPV 59 (5.0 and 4.3% of the analyzed cervi-
cal samples, respectively).
 HPV 16 was the most prevalent genotype in all age 
groups, except for women over 55 years of age, in whom 
HPV 52 had the highest prevalence. It should be noted 
that the prevalence of HPV 16 and HPV 18 decreases with 
age. The prevalence of HPV 39 was higher in women be-
tween 25 and 34 years of age. Overall, almost the same 
HPV types were seen in women aged 24–44 years, when 
the dynamics of the infection dramatically changes ( fig. 3 ).
 Discussion 
 This study provides solid baseline information about 
the distribution of circulating HPV genotypes in women 
with a cytological diagnosis of ASC-US from Bogotá. Fur-
ther, it is the first epidemiological HPV profile performed 
in women enrolled into the PDCCC.
 In this study, 70% (140/200) of the population pre-
sented infection with at least 1 viral genotype. We identi-
fied 32 genotypes, i.e. 14 HR and 18 LR HPV types. A high 
diversity of HPV types was observed in women with a 
cytological diagnosis of ASC-US, especially younger 
women. However, as reported by Molano et al.  [7] , the 
viral heterogeneity of this particular cervical condition 
was no longer seen in severe dysplasia. Thirty percent 
(60/200) of the women showed negative results for HPV 
genetic material, probably because the number of viral 
copies in the sample was below the detection limit of the 
technique, thus preventing the detection of HPV; maybe 
the patient’s immune response favored the elimination or 
clearance of the virus  [9, 12] , because the cytological clas-
sification did not correspond to the initial diagnosis and 
those patients had cervical reactive changes generated by 
other causes.
 Farfán-Vargas et al.  [1] , in a study of women with 
ASC-US from the city of Bogotá, reported an HPV prev-
alence of 20.5%, much lower than that found in the pres-
ent study (70%). The prevalence of single and multiple 
infections found by those authors was 62.9 and 37.1%, 
respectively, being inverted in relation to that found in 
this study, where single infections accounted for 42.9% of 
cases and multiple infections reached 57.1%. Such dis-
crepancy could be associated with the population’s char-
acteristics and the methodological design. In fact, the au-
thors also included women diagnosed with low-grade 
squamous intraepithelial lesions, mostly belonging to 
secondary prevention programs for cervical cancer. Fur-
thermore, those authors used the reverse line blot tech-
nique, whose sensitivity and specificity are different from 
those of the Linear Array technique implemented in the 
present study. As pointed out by other authors, evalua-
tion of multiple infections has a high clinical impact since 
patients with multiple HPV types have increased suscep-
tibility to the development of lesions of the uterine cervix 
 [15] .
 Of the 140 patients infected with HPV, 83.5% (n = 117) 
had HR HPV types and 16.5% (n = 23) had LR HPV ge-
notypes. Although the prevalence and distribution of 
HPV genotypes vary greatly around the world, our data 
are similar to those reported by Delgado et al.  [17] . That 
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 Fig. 2. Prevalence of HPV genotypes in women with ASC-US, cat-
egorized according to simple and multiple infections.  *  HR HPV 
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group conducted an epidemiological study in Spanish 
women with an abnormal cytological diagnosis, using the 
same molecular identification system as ours. Delgado et 
al.  [17] determined a prevalence of 94.3% for HR HPV 
types in Spanish women with a previous diagnosis of 
ASC-US. The reported HPV prevalences were similar to 
those found in this study. HPV 16 was also the most fre-
quent viral type observed in the Spanish population 
(29.7%), followed by HPV 53 (16%), HPV 52 (12%), and 
HPV 39 (10.8%), showing extreme concordance with the 
prevalences found for these viral types in the present 
study. In contrast, HPV 18, 51, and 58 showed quite di-
vergent prevalences. Martín et al.  [18] also analyzed cer-
vical samples from 2,461 women aged 15–75 years with 
cytological abnormalities in central Spain. The genotype 
most frequently found in the ASC-US category was HPV 
16 (31%), followed by HPV 53 (16%) and HPV 31 (11%); 
multiple infections were found in 36% of the analyzed 
samples, indicating that these HPV types shared preva-
lences in different geographical zones.
 Epidemiological data pointed to HPV 58 as the second 
most prevalent HR type in South America, after HPV 16 
 [19] . That status is supported by the findings of this study, 
where HPV 52 and HPV 58 shared almost the same prev-
alence (i.e. 13.6 and 12.9%, respectively). On the other 
hand, Dickson et al.  [20] demonstrated an HPV 18 prev-
alence of 0.8% in US women diagnosed with ASC-US. 
While this prevalence was much lower than that found in 
the present study (7.9%), the obtained data suggest that 
in patients with a cytological ASC-US diagnosis this ge-
notype is not as prevalent as other HR viral types. The 
high prevalence of HPV 52 and 58 found in the present 
study suggests a wide circulation of these HR genotypes 
in the general population, not covered by vaccines, thus 
becoming an important target for the implementation of 
these prophylactic measures.
 The divergences in the type-specific prevalences re-
ported, compared to other studies, may be due to differ-
ences in the techniques employed, and the sensitivity, 
specificity, and genotypes identified by each particular 
test. However, the dynamics of HPV infection are not 
constant and the diversity of women attending the pro-
gram and their sexual and reproductive habits can sig-
nificantly alter the dynamics of this specific viral infec-
tion.
 Different studies  [10, 17] have suggested that HPV in-
fection is most common in young women and that the 
likelihood of infection decreases with increasing age. It 
has been proposed that this situation can be due to the 
concept that in women over 30 years of age the propor-
tion of transient infections is decreased and they develop 
cell-mediated immunity against viral genotypes  [12] or 
reach stability in terms of their sex partner, which gener-
ally occurs in old age  [21] . However, these hypotheses 
have not been elucidated to date  [22] . Furthermore, it has 
been proposed that transient infections are common in 
young women, whereas persistent infections are common 
in older ones  [23] . However, to elucidate whether this 
pattern also occurs in the studied population, persistence 
and follow-up studies are required.
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 The establishment of infections with HPV 16 and 18 
in women with a cytological diagnosis of ASC-US in-
creases the risk of progression to CIN II or III  [24] . There-
fore, it is essential to identify those women with ASC-US 
infected with these HPV types in order to prioritize their 
clinical management and to ensure complete adherence 
to prevention programs.
 This study is the first approach to the epidemiologi-
cal profile of a population with a cytological diagnosis 
of ASC-US enrolled into the PDCCC of a public hospi-
tal network in the city of Bogotá. A high prevalence of 
HPV infection was observed in the analyzed popula-
tion, where HPV 16 had the highest incidence. The data 
obtained in this study can guide actions for epidemio-
logical surveillance, contributing to strengthening of 
the program and outlining of vaccination strategies in 
order to cover the most prevalent HPV types circulating 
in the country.
 Acknowledgments 
 The authors are grateful to the professionals from the PDCCC, 
the District Department of Health, and the research group from 
the Laboratory of Public Health in Bogotá. Thanks are also due to 
A. Di Maggio for editing of this paper.
 Disclosure Statement 
 The authors declare that they have no competing interests.
 
 References 
 1 Farfán-Vargas YA, García-Robayo DA, Arias 
Murillo Y, Morales OL, Isaza M, Aristizábal 
Gutiérrez FA: Genotipificación del virus de 
papiloma humano en mujeres con hallazgo 
citológico de lesión escamosa intraepitelial de 
bajo grado (LSIL) o de significado indetermi-
nado (ASC-US) en Bogotá, Colombia. Rev 
Colomb Cienc Quim Farm 2010; 39: 42–54. 
 2 Ferlay J, Soerjomataram I, Dikshit R, Eser S, 
Mathers C, Rebelo M, Parkin DM, Forman D, 
Bray F: Cancer incidence and mortality 
worldwide: sources, methods and major pat-
terns in GLOBOCAN 2012. Int J Cancer 2015; 
 136:E359–E386. 
 3 Bernard W, Stewart, Wild C: World Cancer 
Report 2014. Lyon, International Agency for 
Research on Cancer, World Health Organiza-
tion, 2014. 
 4 Soto-De Leon S, Camargo M, Sanchez R, Mu-
noz M, Perez-Prados A, Purroy A, et al: Dis-
tribution patterns of infection with multiple 
types of human papillomaviruses and their 
association with risk factors. PLoS One 2011; 
 6:e14705. 
 5 Chao TK, Ke FY, Liao YP, Wang HC, Yu CP, 
Lai HC: Triage of cervical cytological diagno-
ses of atypical squamous cells by DNA meth-
ylation of paired boxed gene 1 (PAX1). Diagn 
Cytopathol 2013; 41: 41–46. 
 6 Zhang S-K, Ci P-W, Velicer C, Kang L-N, Liu 
B, Cui J-F, et al: Comparison of HPV geno-
types and viral load between different sites of 
genital tract: the significance for cervical can-
cer screening. Cancer Epidemiol 2014; 38: 
 168–173. 
 7 Molano M, Posso H, Weiderpass E, Van den 
Brule A, Ronderos M, Franceschi S, et al: 
Prevalence and determinants of HPV infec-
tion among Colombian women with normal 
cytology. Br J Cancer 2002; 87: 324–333. 
 8 Faridi R, Zahra A, Khan K, Idrees M: Onco-
genic potential of Human Papillomavirus. Vi-
rol J 2011; 8: 269. 
 9 Carter JR, Ding Z, Rose BR: HPV infection 
and cervical disease: a review. Aust NZJ Ob-
stet Gynaecol 2011; 51: 103–108. 
 10 Argyri E, Papaspyridakos S, Tsimplaki E, Mi-
chala L, Myriokefalitaki E, Papassideri I, et al: 
A cross sectional study of HPV type preva-
lence according to age and cytology. BMC In-
fect Dis 2013; 13: 53. 
 11 López A, Lizano M: Cáncer cervicouterino y 
el virus del papiloma humano: la historia que 
no termina. Cancerología 2006; 1: 31–55. 
 12 Venezuela RF, Kiguen AX, Frutos MC, Cuffi-
ni CG: Circulation of human papillomavirus 
(HPV) genotypes in women from Córdoba, 
Argentina, with squamous intraepithelial le-
sions. Rev Inst Med Trop São Paulo 2012; 54: 
 11–16. 
 13 Nayar R, Wilbur D: The Bethesda System for 
Reporting Cervical Cytology: Definitions, 
Criteria and Explanatory Notes. Cham, 
Springer, 2015, pp 103–192. 
 14 Wright TC, Stoler MH, Behrens CM, Apple R, 
Derion T, Wright TL: The ATHENA human 
papillomavirus study: design, methods, and 
baseline results. Am J Obstet Gynecol 2012; 
 206: 46.e1–46.e11. 
 15 Barcelos ACM, Michelin MA, Adad SJ, Murta 
EFC: Atypical squamous cells of undeter-
mined significance: Bethesda classification 
and association with human papillomavirus. 
Infect Dis Obstet Gynecol 2011; 2011: 904674. 
 16 Arbyn M, Buntinx F, Van Ranst M, Paraskev-
aidis E, Martin-Hirsch P, Dillner J: Virologic 
versus cytologic triage of women with equivo-
cal Pap smears: a meta-analysis of the accu-
racy to detect high-grade intraepithelial neo-
plasia. J Natl Cancer Inst 2004; 96: 280–293. 
 17 Delgado D, Marín JM, de Diego J, Guerra S, 
González B, Barrios JL, et al: Human papillo-
mavirus (HPV) genotype distribution in 
women with abnormal cervical cytology in 
the Basque Country, Spain. Enferm Infecc 
Microbiol Clin 2012; 30: 230–235. 
 18 Martín P, Kilany L, García D, López-García 
AM, Martín-Azaña MJ, Abraira V, et al: Hu-
man papillomavirus genotype distribution in 
Madrid and correlation with cytological data. 
BMC Infect Dis 2011; 11: 316. 
 19 Shen Y, Gong J-M, Li Y-Q, Gong Y-M, Lei 
D-M, Cheng G-M, et al: Epidemiology and 
genotype distribution of human papillomavi-
rus (HPV) in women of Henan Province, Chi-
na. Clin Chim Acta 2013; 415: 297–301. 
 20 Dickson EL, Vogel RI, Geller MA, Downs LS: 
Cervical cytology and multiple type HPV in-
fection: a study of 8,182 women ages 31–65. 
Gynecol Oncol 2014; 133: 405–408. 
 21 Núñez-Troconis J, Delgado M, González J, 
Mindiola R, Velásquez J, Conde B, et al: Prev-
alence and risk factors of human papillomavi-
rus infection in asymptomatic women in a 
Venezuelan urban area. Invest Clin 2009; 50: 
 203–212. 
 22 Spiryda LB, Brown J, Zhang H, Burgis JT: De-
laying Pap test screening in the adolescent 
population: an evidence-based approach. J 
Pediatr Adolesc Gynecol 2014; 27: 3–5. 
 23 Sijvarger C, González J, Prieto A, Messmer A, 
Mallimaci M, Alonio V, et al: Epidemiología 
de la infección cervical por virus papiloma 
humano en Ushuaia, Argentina. Rev Argent 
Microbiol 2006; 38: 19–24. 
 24 Castle PE, Gage JC, Wheeler CM, Schiffman 
M: The clinical meaning of a cervical intraep-
ithelial neoplasia grade 1 biopsy. Obstet Gy-
necol 2011; 118: 1222–1229. 
 
